IL6 and hepatocellular carcinoma: In order to evaluate the diagnostic value of the IL-6 promoter methylation level as a noninvasive biomarker, we selected PBMCs from HCC patients as the research specimens, using a quantitative high flux methylation detection method–methylight test, which has higher sensitivity and specificity than traditional MSP technology (15, 45).